Holen Sie sich die Stockscreener-App
14.21
0.11%
-0.015
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
What’s Behind Iovance Biotherapeutics (IOVA) Latest Move? - Simply Wall Street
Iovance appoints Noah Berkowitz as chief medical officer - Investing.com
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., As Chief Medical Officer - TradingView
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire
Iovance Biotherapeutics Is Maintained at Overweight by Wells Fargo - Moomoo
IOVA Stock Soars As Revenue Outlook Jumps And Analysts Chase - StocksToTrade
IOVA Stock Surges As Revenue Guidance Reset Triggers Bull Run - timothysykes.com
IOVA Maintains Rating by Wells Fargo -- Price Target Raised to $18 - GuruFocus
Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On? - Benzinga
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 - TradingView
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains? - Yahoo Finance
Iovance Stock Surges as Strong Melanoma Drug Demand Drives Growth -- Barrons.com - Moomoo
Fair Issac Corp., Iovance Biotherapeutics, Stablecoin Development Corp., Carnival Corp. and Micron: Why T - Benzinga
Iovance Biotherapeutics (IOVA) Eyes 60% Revenue Growth, Shares Jump 31% - Yahoo Finance
Cash flow from financing activities of Iovance Biotherapeutics Inc – HAN:2LB - TradingView
Iovance: The Turnaround Is Priced In, Downgrading To Hold (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics raises 2026 revenue for... - Pluang
Iovance Biotherapeutics (IOVA) Shares Surge Over 30% After Raisi - GuruFocus
Update: Iovance Biotherapeutics Shares Jump After 2026 Revenue Guidance Raised - Yahoo Finance
Iovance stock rises as analysts cheer new outlook (IOVA:NASDAQ) - Seeking Alpha
Iovance Lifts 2026 Revenue Outlook by $55 Million on Amtagvi Demand, Shares Hit Two-Year High - finance.biggo.com
Iovance Biotherapeutics, Inc. stock Analysis: 2026 Rally Meets Overbought Alerts - The Cryptonomist
Iovance Biotherapeutics Surges After Lifting 2026 Revenue Outlook - Moomoo
Iovance Raises 2026 Revenue Guidance on Strong Demand - grafa.com
Iovance Biotherapeutics’ Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars - TradingView
Iovance Stock Surges as Strong Melanoma Drug Demand Drives Growth - Barron's
IOVA Maintained by HC Wainwright & Co. -- Price Target Raised to $20 - GuruFocus
HC Wainwright & Co. maintains Buy rating on Iovance Biotherapeutics, $20 price target - TradingView
CarMax Posts Upbeat Q2 Earnings, Joins Iovance Biotherapeutics, Perella Weinberg Partners And Other Big S - Benzinga
IOVA Stock Hits Over 2-Year Highs – Why Iovance Raised Its FY2026 Revenue Outlook - Yahoo Finance
Iovance Raises 2026 Revenue Guidance to $410 Million-$420 Million - Yahoo Finance
Iovance Biotherapeutics Stock Draws Bullish Targets As Amtagvi Launch Turns - timothysykes.com
IOVA Stock Draws Bullish Targets As Amtagvi Momentum Builds - StocksToTrade
Iovance shares jump in premarket as raised outlook clears consensus views - Investing.com
Form 8K Iovance Biotherapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Why is Iovance Biotherapeutics stock surging today? By Investing.com - Investing.com Nigeria
Iovance Biotherapeutics (IOVA) Raises 2026 Revenue Forecast Above Analyst Estimates - GuruFocus
Iovance raises 2026 revenue guidance to $410-420 million - Investing.com
Iovance Biotherapeutics Raises 2026 Revenue Guidance Outlook - TipRanks
Iovance Biotherapeutics Raises 2026 Revenue Guidance - marketscreener.com
Nearly 60% revenue growth is implied by Iovance's 2026 forecast. - Stock Titan
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million - Yahoo Finance
How (IOVA) Movements Inform Risk Allocation Models - Stock Traders Daily
Why Did IOVA Stock Gain Pre-Market Today? - Stocktwits
Iovance Biotherapeutics, Inc. (IOVA) Options Chain - Yahoo! Finance Canada
IOVA Stock Hits Fresh 52-Week Peak On UBS Target Hike, Melanoma Sector Optimism - Stocktwits
Iovance Biotherapeutics stock hits 52-week high at 10.98 USD - Investing.com
Iovance Biotherapeutics stock hits 52-week high at 10.98 USD By Investing.com - Investing.com Nigeria
Iovance Biotherapeutics Price Target Announced at $15.00/Share by Goldman Sachs - moomoo.com
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
IOVA Stock Price, Quote & Chart - ChartMill
Why Iovance Biotherapeutics Stock Was on Fire Today - The Motley Fool
IOVA Reinstated by Goldman Sachs -- Buy Rating with Price Target of $15.00 - GuruFocus
Goldman Sachs Reinstates Buy on Iovance Biotherapeutics (IOVA) w - GuruFocus
Iovance Biotherapeutics (IOVA) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
IOVA Stock Quote Price and Forecast - CNN
Iovance Biotherapeutics, Inc. (IOVA) stock price, news, quote and history - Yahoo Finance UK
Iovance Biotherapeutics, Inc. (IOVA) Stock Price, News, Quote & History - Yahoo! Finance Canada
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits
Iovance Biotherapeutics Inc (IOVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Iovance Biotherapeutics stock extends rally after strong earnings and cancer therapy momentum - AD HOC NEWS
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate - Zacks Investment Research
Iovance Biotherapeutics Stock: 6 Straight Green Days, Up 26% - Trefis
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):